These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 9142794)

  • 21. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
    Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
    Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
    Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.
    Shinefield H; Black S; Williams WR; Marchant C; Reisinger K; Stewart T; Meissner HC; Guerrero J; Klopfer SO; Xu J; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2005 Aug; 24(8):670-5. PubMed ID: 16094218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined vaccine against measles, mumps, rubella, and varicella.
    Brunell PA; Novelli VM; Lipton SV; Pollock B
    Pediatrics; 1988 Jun; 81(6):779-84. PubMed ID: 2835743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity.
    Hesley TM; Reisinger KS; Sullivan BJ; Jensen EH; Stasiorowski S; Meechan C; Chan CY; West DJ;
    Pediatr Infect Dis J; 2004 Mar; 23(3):240-5. PubMed ID: 15014300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age.
    Haas H; Richard P; Eymin C; Fiquet A; Kuter B; Soubeyrand B
    Hum Vaccin Immunother; 2019; 15(4):778-785. PubMed ID: 30481110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore: a phase II, randomized, double-blind trial.
    Huang LM; Lee BW; Chan PC; Povey M; Henry O
    Hum Vaccin Immunother; 2013 Jun; 9(6):1308-15. PubMed ID: 23425607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH; Saracen CL; Peter G
    Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.
    MMR-158 Study Group
    Hum Vaccin Immunother; 2019; 15(4):786-799. PubMed ID: 30785357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New vaccines and vaccination policies.
    Pichichero ME; Green JL; Francis AB; Marsocci SM; Disney FA
    Pediatr Ann; 1990 Dec; 19(12):686-8, 690-1, 694. PubMed ID: 2177872
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad).
    Kuter BJ; Brown ML; Hartzel J; Williams WR; EvesiKaren A; Black S; Shinefield H; Reisinger KS; Marchant CD; Sullivan BJ; Thear M; Klopfer S; Xu J; Gress JO; Schödel F;
    Hum Vaccin; 2006; 2(5):205-14. PubMed ID: 17035730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new combination vaccine for measles, mumps, rubella and varicella.
    Zareba G
    Drugs Today (Barc); 2006 May; 42(5):321-9. PubMed ID: 16801995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines.
    Deforest A; Long SS; Lischner HW; Girone JA; Clark JL; Srinivasan R; Maguire TG; Diamond SA; Schiller RP; Rothstein EP
    Pediatrics; 1988 Feb; 81(2):237-46. PubMed ID: 3340474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context.
    Casabona G; Berton O; Singh T; Knuf M; Bonanni P
    Expert Rev Vaccines; 2023; 22(1):764-776. PubMed ID: 37642012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interference between strains in live virus vaccines. II: Combined vaccination with varicella and measles-mumps-rubella vaccine.
    Berger R; Just M
    J Biol Stand; 1988 Oct; 16(4):275-9. PubMed ID: 2848843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.